drugset / Trial / NCT02345291
Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
A multicenter, Phase 2a, randomized, double-blind, placebo (vehicle)-controlled, parallel-group, dose-finding study designed to evaluate the efficacy, safety and tolerability of NRD135S.E1 in adult patients with diabetes mellitus type 1 or 2 with neuropathic pain. Potential study patients will sign informed consent prior to undergoing any study-related procedure.
Timeline
- Start
- 2015-04
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NRD135S.E1 | Small molecule | 10 mg | Oral |
| Subject | NRD135S.E1 | Small molecule | 40 mg | Oral |
| Subject | NRD135S.E1 | Small molecule | 150 mg | Oral |